Glasdegib in combination with cytarabine and daunorubicin in patients with AML or high ‐risk MDS: Phase 2 study results

American Journal of Hematology,Volume 0, Issue ja, -Not available-.

Source: American Journal of Hematology - August 3, 2018 Category: Hematology Authors: Jorge E. Cortes MD , B. Douglas Smith MD , Eunice S. Wang MD , Akil Merchant MD , Vivian G. Oehler MD , Martha Arellano MD , Daniel J. DeAngelo MD , Daniel A. Pollyea MD , Mikkael A. Sekeres MD , Tadeusz Robak MD , Source Type: research